Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the ...

Eli Lilly and Company has agreed to acquire Adverum Biotechnologies Inc., a clinical-stage company pioneering the use of intravitreal gene therapy.

Eli Lilly plans to acquire a gene therapy developer that once planned a 200-job facility in Research Triangle Park.

Adverum Biotechnologies (($ADVM)) announced an update on their ongoing clinical study. Adverum Biotechnologies is conducting a Phase 3 clinical ...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest ...

Eli Lilly and Company and Adverum Biotechnologies, a clinical-stage gene therapy company aiming to preserve sight for life in ...

Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...

US markets wrapped up the week on a high note, with strong earnings and cooling inflation data propelling both major indices to new records. The S&P 500 broke 6 800 for the first time with ...